Background Incidence of whooping cough is increasing in Korea. Since 2011, occurrence
among adolescents and adults has risen putting vulnerable neonates at risk. National …

抄録 Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine is
generally used for booster vaccination of infants in Europe and the United States to avoid …

In light of waning immunity to pertussis following receipt of tetanus toxoid, reduced
diphtheria toxoid and acellular pertussis (Tdap) vaccine, maintaining protection may require …

Pertussis is an acute respiratory infection characterized by paroxysmal cough and
inspiratory whoop for over 2 weeks. The incidence of pertussis has decreased markedly …

Summary On June 10, 2005, a tetanus toxoid, reduced diphtheria toxoid and acellular
pertussis vaccine (Tdap) formulated for use in adults and adolescents was licensed in the …

Compared with older children and adults, infants aged < 12 months have substantially
higher rates of pertussis and the largest burden of pertussis-related deaths. Since 2004, a …

Background: Prelicensure clinical studies may not include sufficient numbers of subjects to
assess the potential for rare postvaccination adverse events. The aim of this postlicensure …

Background This study assessed the safety and immunogenicity of a new booster vaccine
against tetanus, diphtheria, and pertussis manufactured by Serum Institute of India Pvt. Ltd …

Background Two Tdap vaccines are licensed for use in the United States. Boostrix
(GlaxoSmithKline) is approved for a single dose in persons aged≥ 10 years; Adacel (Sanofi …

Methods In monthly teleconferences during 2012, the ACIP Pertussis Vaccines Work Group
considered published, peer-reviewed literature and unpublished data relevant to …